Breaking News

Biogen Idec, Eisai in Manufacturing Alliance

December 12, 2012

Covers solid dosage, vial-filling activity

Biogen Idec and Eisai have entered a strategic alliance aimed at bolstering the manufacturing capabilities of both companies’ facilities in Research Triangle Park (RTP). Biogen will lease a portion of the Eisai facility to manufacture oral solid dose products for both companies and Eisai will provide Biogen with vial-filling services for biologic therapies and packaging services for oral solid dose products.
Under the 10-year lease agreement, Biogen has the option to purchase Eisai’s oral solid dose facility. Approximately 50 Eisai personnel are expected to become Biogen employees in early 2013. Eisai currently has approximately 225 full-time employees at its RTP site.
“We view our supply chain as a lifeline to patients, designed to deliver quality therapies wherever and whenever they are needed,” said John G. Cox, executive vice president of Pharmaceutical Operations and Technology, for Biogen Idec. “This innovative capacity-sharing relationship with Eisai fits strategically in our global drug supply network, particularly as we advance our oral therapeutics.”
"We look forward to collaborating with Biogen Idec to continue the proud history of drug manufacturing excellence here at our RTP site," said Lou Arp, general manager of the Eisai RTP site and president of Global Oncology Manufacturing, for Eisai Inc. "Our alliance will enable both companies to focus on respective areas of expertise while continuing to deliver high-quality and innovative products to patients. Moreover, employees will benefit by working in a highly collaborative environment that offers opportunities to further cultivate their careers.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks